Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab191894-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$99.90
|
|
|
Ab191894-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$479.90
|
|
|
Ab191894-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,429.90
|
|
|
Ab191894-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,289.90
|
|
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Benufutamab (anti-TNFRSF10B) - Primary antibody, specific to TNFRSF10B, Human IgG1 |
|---|---|
| Synonyms | Fas like protein antibody | Apoptosis inducing protein TRICK2A/2B antibody | Apoptosis inducing receptor TRAIL R2 antibody | CD262 antibody | CD262 antigen antibody | Cytotoxic TRAIL receptor 2 antibody | Death domain containing receptor for TRAIL/Apo 2L |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade |
| Host species | Human |
| Specificity | TNFRSF10B |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Benufutamab (anti-TNFRSF10B) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab (anti-TNFRSF10B) is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab (anti-TNFRSF10B) has antitumor effects. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 2109730-69-8 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Benufutamab (anti-TNFRSF10B) (Ab191894) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling TNFRSF10B (red) with Benufutamab (anti-TNFRSF10B) (Ab191894) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Benufutamab (anti-TNFRSF10B) (Ab191894) - SEC
The purity of Benufutamab (anti-TNFRSF10B) (Ab191894) is more than 95% verified by HPLC.
Benufutamab (anti-TNFRSF10B) (Ab191894) - ELISA
Immobilized Recombinant Human TRAIL R2/TNFRSF10B protein (rp145269) at 0.5 μg/mL can bind Benufutamab (anti-TNFRSF10B) (Ab191894) with the EC50 of 271.1 ng/mL.
Starting at $109.90
Starting at $69.90